GlassScriptPhysician profile
Samuel R Anderson
NPI 1902883135
$556,467.32
in general payments reported to CMS, 2019-2025
60 companies · $49K in 2025
The $49K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155K · 2020: $63K · 2021: $66K · 2022: $99K · 2023: $65K · 2024: $59K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $157K · Travel and Lodging: $9,026 · Food and Beverage: $8,012 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $156,659.44 |
| Travel and Lodging | $9,026.14 |
| Food and Beverage | $8,011.60 |
| Education | $154.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $215,640.07 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $136,874.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $65,618.26 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $56,626.38 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35,632.60 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $14,604.51 | 2019-2022 | |
| Amgen INC. | $8,398.86 | 2019-2025 | Evenity, Tepezza, Prolia |
| Xeris Pharmaceuticals, INC. | $5,472.73 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $5,378.21 | 2019-2024 | Cycloset |
| Mannkind Corporation | $3,197.68 | 2019-2024 | |
| Medtronic Minimed, INC. | $1,774.81 | 2019-2020 | |
| Dexcom, INC. | $868.62 | 2019-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $499.62 | 2019-2025 | Korlym |
| Insulet Corporation | $473.57 | 2019-2025 | Omnipod |
| Abbott Laboratories | $466.30 | 2020-2025 | Freestyle Libre 3 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $443.85 | 2021-2025 | Minimed 780g, Inceptiv |
| Abbvie INC. | $405.07 | 2019-2025 | Synthroid |
| Bayer Healthcare Pharmaceuticals INC. | $322.30 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $316.40 | 2022-2025 | |
| Radius Health, INC. | $271.69 | 2019-2025 | Tymlos |
| Amneal Pharmaceuticals LLC | $269.06 | 2019-2025 | Unithroid |
| Antares Pharma, INC. | $244.31 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Beta Bionics, INC. | $216.94 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Esperion Therapeutics, INC. | $178.65 | 2021-2025 | Nexletol |
| Ibsa Pharma INC. | $176.08 | 2019-2025 | Tirosint, Licart, Tirosint |
| Cequr Corporation | $175.20 | 2022-2025 | Cequr Simplicity |
| Pfizer INC. | $159.87 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $150.77 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Avvisto Therapeutics, LLC | $148.31 | 2025 | Cycloset |
| Almatica Pharma LLC | $109.24 | 2024 | Teriparatide |
| Recordati_rare_diseases_inc. | $105.95 | 2021-2025 | Isturisa, Signifor Lar |
| Merck Sharp & Dohme LLC | $99.50 | 2019-2023 | Steglatro, Segluromet, Steglujan |
| Alexion Pharmaceuticals, INC. | $95.59 | 2021-2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $77.77 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $73.62 | 2025 | Twiist |
| Tolmar, INC. | $70.09 | 2023-2025 | Jatenzo |
| Janssen Pharmaceuticals, INC | $68.33 | 2019 | |
| Lifescan, INC. | $67.36 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $55.68 | 2024-2025 | |
| Shire North American Group INC | $52.60 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $52.20 | 2019 | |
| Eusa Pharma (US) LLC | $50.02 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $48.50 | 2020-2022 | |
| Kyowa Kirin, INC. | $47.62 | 2024-2025 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $46.45 | 2021-2024 | Crysvita |
| Nevro Corp. | $39.32 | 2022 | |
| Averitas Pharma INC. | $35.83 | 2024-2025 | Qutenza |
| Horizon Therapeutics Plc | $32.30 | 2020-2021 | |
| Amryt Pharma Holdings LTD | $27.39 | 2021-2022 | |
| Echosens North America, INC. | $26.08 | 2024 | Fibroscan |
| Zealand Pharma US, INC. | $24.65 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $22.53 | 2024 | Rayaldee |
| Endo USA, INC. | $21.79 | 2024 | Aveed |
| Amphastar Pharmaceuticals, INC. | $20.13 | 2024 | |
| Valeritas, INC. | $18.79 | 2019 | |
| Roche Diabetes Care, INC. | $16.89 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $16.15 | 2023 | Somatuline Depot |
| Halozyme INC | $14.72 | 2023 | |
| Ascensia Diabetes Care US INC. | $14.08 | 2024 | |
| Clarus Therapeutics INC. | $10.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.